IJCS | Volume 32, Nº5, September/October 2019

495 Cont. Table 1 - Characteristics of the 53 patients included in the study Number/total and (%) LV ejection fraction: LVEF (mean ± SD) 58.83 ± 16.67 LVEF < 40% 9/53 (17.0%) LV/AO gradients in mmHg: Mean LV/AO grad (mean ± SD) 53.4 ± 18.7 Maximum LV/AO grad (mean ± SD) 80.8 ± 22.6 LV hypertrophy 44/53 (83.0%) Mitral annulus calcification 28/53 (52.8%) SD: standard deviation; IQR: interquartile range; PCI: percutaneous coronary intervention; CABG: coronary artery bypass grafting; TIA: transient ischemic attack; COPD: chronic obstructive pulmonary disease; LV: left ventricle; FE: ejection fraction; Grad: gradient; AO: aorta. Table 2 - Echocardiographic characteristics of patients Number/total and (%) Cardiac rhythm Sinus rhythm 39/53 (73.6%) Atrial fibrillation or flutter 14/53 (26.4%) HR (mean ± SD) 72 bpm ± 13.2 HR < 60 bpm 8/52 (15.1%) First-degree AV block 7/41 (13.2%) Median PR interval [IQR] 160 ms [160 – 200] Median QRS duration [IQR] 100 ms [80 – 140] LBBB 9/52 (17.0%) RBBB 9/52 (17.0%) LAHB 11/52 (20.8%) LPHB 0/52 (0%) LBBB or RBBB 18/52 (34.0%) First-degree AVB or bundle branch block 20/52 (38.4%) IQR: interquartile range; LBBB: left bundle branch block; RBBB: right bundle branch block; LAHB: left anterior hemiblock; LPHB: left posterior hemiblock; AVB: atrioventricular block. Table 3 - Echocardiographic variables of the procedure Number/total Type of prosthesis: CoreValve ® 39/53 (73.6%) Sapien ® 8/53 (15.1%) Inovare ® 6/53 (11.2%) Pre-dilatation with balloon 16/53 (30.2%) Need for 2 nd valve (valve-in-valve) 7/53 (13.2%) Prosthesis size in mm (mean ± SD) 27 ± 2.60 Access routes: Femoral artery 43/53 (81.1%) Transapical 6/53 (11.3%) Transaortic 3/53 (5.70%) Subclavian artery 1/53 (1.90%) Cedenilla et al. Requirements for permanent pacemaker afterTAVI Int J Cardiovasc Sci. 2019;32(5):492-504 Original Article Most patients (39 of 53 - 73.6%) had the CoreValve ® prosthesis implanted. Eight received Sapien ® (15.1%) and 6 received Inovare ® (11.2%) (table 3). The sizes of the prostheses usedwere: number 20 (1 Inovare ® prosthesis), number 23 (6 Sapien ® prostheses), number 24 (1 Inovare ® prosthesis), number 26 (1 Sapien ® prosthesis, 2 Inovare ® prostheses and 14 CoreValve ® prostheses), number 28 (1 Inovare ® prosthesis), number 29 (1 Sapien ® prosthesis and 19 CoreValve ® prostheses), number 30 (1 Inovare ® prosthesis) and number 31 (6 CoreValve ® prostheses). Balloon pre-dilation was performed in only 30% of the cases. In 7 patients, a second prosthesis was implanted (CoreValve ® in CoreValve ® ). The femoral artery was the most used access route (81% of the cases) followed by the transapical route. Incidence of new conduction disorders and need for pacemaker Fortyofthe52patients(77%)developednewconduction disorders after TAVI, with 23 new atrioventricular conduction disorders, 13 new interventricular conduction disorders and 4 new mixed conduction disorders (first- degree AVB and concomitant LBBB). (Figure 1) Twelve of the 52 (23%) ECG patients available for analysis did not develop new conduction disorders after TAVI. None of them died. Eight of these 12 patients had